Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 351

Results For "ED"

11247 News Found

Indoco's formulation plant at Baddi receives EU GMP certification
News | June 01, 2026

Indoco's formulation plant at Baddi receives EU GMP certification

This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive


National Policy Dialogue adopts landmark 10-point declaration for people with disabilities
Healthcare | June 01, 2026

National Policy Dialogue adopts landmark 10-point declaration for people with disabilities

World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection


Insect biotech as India's next deeptech opportunity: Ankit Alok Bagaria, Co-founder and CEO, Loopworm
Opinion | June 01, 2026

Insect biotech as India's next deeptech opportunity: Ankit Alok Bagaria, Co-founder and CEO, Loopworm

We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms


Pfizer and Innovent Biologics strike $10 billion cancer drug deal
News | June 01, 2026

Pfizer and Innovent Biologics strike $10 billion cancer drug deal

This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants


Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections
Drug Approval | June 01, 2026

Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance


Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial
Clinical Trials | June 01, 2026

Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial

The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival


Ardena appoints Ariane de Ganck as Chief Scientific Officer
People | June 01, 2026

Ardena appoints Ariane de Ganck as Chief Scientific Officer

Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022


Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
R&D | May 31, 2026

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease


AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
Clinical Trials | May 31, 2026

AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia

The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,


Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting
Drug Approval | May 30, 2026

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial